ZA200100827B - Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure. - Google Patents
Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure.Info
- Publication number
- ZA200100827B ZA200100827B ZA200100827A ZA200100827A ZA200100827B ZA 200100827 B ZA200100827 B ZA 200100827B ZA 200100827 A ZA200100827 A ZA 200100827A ZA 200100827 A ZA200100827 A ZA 200100827A ZA 200100827 B ZA200100827 B ZA 200100827B
- Authority
- ZA
- South Africa
- Prior art keywords
- acute
- renal failure
- receptor
- prostaglandin
- chronic renal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17896800P | 2000-01-31 | 2000-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200100827B true ZA200100827B (en) | 2002-07-30 |
Family
ID=22654657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200100827A ZA200100827B (en) | 2000-01-31 | 2001-01-30 | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure. |
Country Status (18)
Country | Link |
---|---|
US (1) | US6610719B2 (da) |
EP (1) | EP1132086B1 (da) |
JP (2) | JP3839261B2 (da) |
KR (1) | KR100419684B1 (da) |
AT (1) | ATE327751T1 (da) |
AU (1) | AU774569B2 (da) |
CA (1) | CA2332687A1 (da) |
CO (1) | CO5261529A1 (da) |
CY (1) | CY1105299T1 (da) |
DE (1) | DE60120007T2 (da) |
DK (1) | DK1132086T3 (da) |
ES (1) | ES2263557T3 (da) |
HU (1) | HUP0100495A3 (da) |
IL (1) | IL141120A0 (da) |
NZ (1) | NZ509632A (da) |
PE (1) | PE20011048A1 (da) |
PT (1) | PT1132086E (da) |
ZA (1) | ZA200100827B (da) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024647A1 (fr) * | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
DE60130675T2 (de) | 2000-11-27 | 2008-01-24 | Pfizer Products Inc., Groton | Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose |
EP1408961B1 (en) * | 2001-07-16 | 2007-07-11 | F. Hoffmann-La Roche Ag | 2 pyrrolidone derivatives as prostanoid agonists |
KR100826866B1 (ko) | 2001-07-23 | 2008-05-06 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제 |
AU2002340282B2 (en) | 2001-10-23 | 2007-08-09 | Merck Serono Sa | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors |
US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
AU2003211574A1 (en) | 2002-03-05 | 2003-09-16 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
AU2003209571A1 (en) * | 2002-03-18 | 2003-09-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
AU2003233729B2 (en) * | 2002-06-06 | 2007-10-04 | Merck Frosst Canada Ltd | 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma |
JP4754820B2 (ja) * | 2002-06-10 | 2011-08-24 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγラクタムおよびその使用 |
HUE029417T2 (en) | 2002-10-10 | 2017-02-28 | Ono Pharmaceutical Co | Microspheres containing ONO-1301 |
FI20030015A0 (fi) * | 2003-01-03 | 2003-01-03 | Orion Corp | Menetelmä munuaisten vajaatoiminnan hoitamiseksi |
EP1586564B1 (en) * | 2003-01-21 | 2012-11-28 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medicinal uses thereof |
GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
US20080306155A1 (en) * | 2004-09-16 | 2008-12-11 | Roman Richard J | Method for treating renal disease |
US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
WO2008073748A1 (en) | 2006-12-08 | 2008-06-19 | University Of Rochester | Expansion of hematopoietic stem cells |
EP1952823A1 (en) | 2007-01-30 | 2008-08-06 | AM-Pharma B.V. | The use of alkaline phosphatase in the treatment of reduced renal function |
JP5836262B2 (ja) | 2009-03-19 | 2015-12-24 | フェイト セラピューティクス, インコーポレイテッド | サイクリックampエンハンサーおよび/またはepリガンドを含む組成物、ならびにこれを調製および使用する方法 |
CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
CN102933233A (zh) | 2010-06-17 | 2013-02-13 | 日东电工株式会社 | 肾纤维化处理剂 |
ES2654994T3 (es) | 2010-08-12 | 2018-02-15 | Fate Therapeutics, Inc. | Terapia mejorada con células madre y precursoras hematopoyéticas |
KR20140056250A (ko) | 2011-08-02 | 2014-05-09 | 오노 야꾸힝 고교 가부시키가이샤 | 좌심실 확장 기능 개선제 |
SG10201602423TA (en) | 2011-09-30 | 2016-05-30 | Bluebird Bio Inc | Compounds For Improved Viral Transduction |
JP6220791B2 (ja) | 2011-12-02 | 2017-10-25 | フェイト セラピューティクス,インコーポレイテッド | 増強された幹細胞組成物 |
WO2013082241A2 (en) | 2011-12-02 | 2013-06-06 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
WO2014069401A1 (ja) | 2012-10-29 | 2014-05-08 | 株式会社カルディオ | 肺疾患特異的治療剤 |
US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
EP2968416A4 (en) | 2013-03-15 | 2016-08-17 | Fate Therapeutics Inc | BIOLOGICAL ACTIVITY TESTING OF CELLS FOR A THERAPEUTIC POTENTIAL |
JP6449166B2 (ja) | 2013-10-15 | 2019-01-09 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
BR112016017041B1 (pt) | 2014-01-24 | 2023-09-26 | Am-Pharma B.V | Proteína quimérica isolada, vetor, método para produzir a proteína quimérica isolada e composição |
PL3461891T3 (pl) | 2014-01-24 | 2020-11-16 | Am-Pharma B.V. | Przetwarzanie końcowe fosfatazy alkalicznej |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
EP3770252A1 (en) | 2015-01-26 | 2021-01-27 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
EP3307747A4 (en) | 2015-06-12 | 2019-02-27 | Simon Fraser University | AMIDE-LINKED EP4-BISPHOSPHONATE AGONIST COMPOUNDS AND USES THEREOF |
WO2017015320A1 (en) | 2015-07-21 | 2017-01-26 | Children's Medical Center Corporation | Pd-l1 expressing hematopoietic stem cells and uses |
CA3014078A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
WO2017139561A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
EP4146797A1 (en) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4066692A (en) | 1972-10-30 | 1978-01-03 | Merck & Co., Inc. | 11,12-secoprostaglandins |
US3987091A (en) | 1973-04-12 | 1976-10-19 | Merck & Co., Inc. | 11,12-secoprostaglandins |
US4033996A (en) | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
SE7414770L (da) | 1973-12-13 | 1975-06-16 | Merck & Co Inc | |
US3991087A (en) | 1973-12-13 | 1976-11-09 | Merck & Co., Inc. | 8-Halo-11,12-secoprostaglandins |
DK366475A (da) | 1974-08-30 | 1976-03-01 | Merck & Co Inc | Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner |
US3991106A (en) | 1974-09-13 | 1976-11-09 | Merck & Co., Inc. | 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins |
US4055596A (en) | 1974-09-13 | 1977-10-25 | Merck & Co., Inc. | 11,12-Seco-prostaglandins |
US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
CA1077948A (en) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | 1,-5 disubstituted-2-pyrrolidones and processes for their production |
US4175203A (en) | 1976-12-17 | 1979-11-20 | Merck & Co., Inc. | Interphenylene 11,12-secoprostaglandins |
US4112236A (en) | 1977-04-04 | 1978-09-05 | Merck & Co., Inc. | Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins |
US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
US5716835A (en) | 1994-05-05 | 1998-02-10 | Allergan, Inc. | Nucleic acid encoding a novel human EP prostaglandin receptor |
US5807895A (en) * | 1994-11-29 | 1998-09-15 | Schwarz Pharma, Inc. | Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
US6531485B2 (en) | 1997-06-23 | 2003-03-11 | Pfizer Inc. | Prostaglandin agonists |
SE9702681D0 (sv) | 1997-07-10 | 1997-07-10 | Pharmacia & Upjohn Ab | Method and composition for treatment of impotence |
UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
US6124314A (en) | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
TWI249520B (en) * | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
EP1114816A4 (en) * | 1998-09-14 | 2002-09-04 | Ono Pharmaceutical Co | SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT |
WO2000054808A1 (fr) * | 1999-03-16 | 2000-09-21 | Toray Industries, Inc. | Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant |
-
2001
- 2001-01-25 AT AT01300690T patent/ATE327751T1/de not_active IP Right Cessation
- 2001-01-25 ES ES01300690T patent/ES2263557T3/es not_active Expired - Lifetime
- 2001-01-25 IL IL14112001A patent/IL141120A0/xx unknown
- 2001-01-25 DE DE60120007T patent/DE60120007T2/de not_active Expired - Fee Related
- 2001-01-25 EP EP01300690A patent/EP1132086B1/en not_active Expired - Lifetime
- 2001-01-25 PT PT01300690T patent/PT1132086E/pt unknown
- 2001-01-25 DK DK01300690T patent/DK1132086T3/da active
- 2001-01-29 PE PE2001000097A patent/PE20011048A1/es not_active Application Discontinuation
- 2001-01-29 CA CA002332687A patent/CA2332687A1/en not_active Abandoned
- 2001-01-29 US US09/771,164 patent/US6610719B2/en not_active Expired - Fee Related
- 2001-01-30 JP JP2001021534A patent/JP3839261B2/ja not_active Expired - Fee Related
- 2001-01-30 AU AU16722/01A patent/AU774569B2/en not_active Ceased
- 2001-01-30 NZ NZ509632A patent/NZ509632A/xx unknown
- 2001-01-30 HU HU0100495A patent/HUP0100495A3/hu unknown
- 2001-01-30 ZA ZA200100827A patent/ZA200100827B/xx unknown
- 2001-01-31 CO CO01007013A patent/CO5261529A1/es not_active Application Discontinuation
- 2001-01-31 KR KR10-2001-0004590A patent/KR100419684B1/ko not_active IP Right Cessation
-
2006
- 2006-02-24 JP JP2006047746A patent/JP2006182788A/ja active Pending
- 2006-07-04 CY CY20061100920T patent/CY1105299T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60120007T2 (de) | 2006-11-16 |
JP3839261B2 (ja) | 2006-11-01 |
DK1132086T3 (da) | 2006-08-28 |
JP2001233792A (ja) | 2001-08-28 |
CY1105299T1 (el) | 2010-03-03 |
US20010041729A1 (en) | 2001-11-15 |
HU0100495D0 (en) | 2001-03-28 |
KR100419684B1 (ko) | 2004-02-21 |
AU774569B2 (en) | 2004-07-01 |
EP1132086B1 (en) | 2006-05-31 |
PE20011048A1 (es) | 2001-10-19 |
AU1672201A (en) | 2001-08-02 |
EP1132086A2 (en) | 2001-09-12 |
NZ509632A (en) | 2003-01-31 |
EP1132086A3 (en) | 2002-01-09 |
KR20010078209A (ko) | 2001-08-20 |
HUP0100495A2 (en) | 2002-10-28 |
DE60120007D1 (de) | 2006-07-06 |
ATE327751T1 (de) | 2006-06-15 |
PT1132086E (pt) | 2006-09-29 |
CA2332687A1 (en) | 2001-07-31 |
ES2263557T3 (es) | 2006-12-16 |
JP2006182788A (ja) | 2006-07-13 |
IL141120A0 (en) | 2002-02-10 |
CO5261529A1 (es) | 2003-03-31 |
HUP0100495A3 (en) | 2003-12-29 |
US6610719B2 (en) | 2003-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200100827B (en) | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure. | |
IL153406A0 (en) | Cyclopentanoindoles, compositions containing such compounds and methods of treatment | |
EA200300387A1 (ru) | Ингибиторы рецептора ep4 для лечения ревматоидного артрита | |
BG110174A (en) | Substituted arylpyrazines | |
EE200300246A (et) | EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks | |
WO2000056301A3 (en) | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders | |
TR200909479T2 (tr) | Sinerjistik kombinasyon. | |
BG102726A (en) | Combined therapy for osteoporosis | |
DK1225881T3 (da) | Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion | |
EP1108426A3 (en) | Use of prostaglandin agonists to treat erectile dysfunction or impotence | |
NO20033959L (no) | Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon | |
DE60029242D1 (de) | Arzneien zur begleitenden behandlung von glaukomen | |
NZ512137A (en) | Prostaglandin E2 (PGE2) and PGE4 analogues, which are antagonists of the EP2 receptor for treatment of female sexual dysfunction | |
WO2002041894A3 (en) | Selective dopamine d4 receptor agonists for treating sexual dysfunction | |
IT1293804B1 (it) | Diarilalchilpiperazine attive sulle basse vie urinarie | |
MXPA04003910A (es) | Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar. | |
DK1455770T3 (da) | Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser | |
WO2001035945A3 (en) | Use of prostaglandin a2 for the treatment and prophylaxis of priapism | |
DE60218024D1 (de) | Neue zusatzstoffe zur verhinderung des verbackens pulverförmiger emulgatoren | |
ES2188144T3 (es) | Dispositivo para el tratamiento de agua. | |
BR9908392A (pt) | Uso de antagonistas de d1/d5 para o tratamento de distúrbios obsessivos compulsivos, distúrbios somatofórmicos, distúrbios dissociativos, distúrbios de alimentação, distúrbios de controle de impulsos e autismo | |
WO2003003983A3 (en) | Receptor agonists useful for the treatment of pain | |
MY155220A (en) | Selective dopamine d4 receptor agonists for treating sexual dysfunction | |
EP1581759A4 (en) | METHODS OF TREATING TAXOL INDUCED SENSORY NEUROPATHY |